Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

major pharmaceuticals - paliperidone (unii: 838f01t721) (paliperidone - unii:838f01t721) - paliperidone extended-release tablets are indicated for the treatment of schizophrenia [see clinical studies (14.1)] . the efficacy of paliperidone extended-release tablets in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents, as well as one maintenance trial in adults. paliperidone extended-release tablets are indicated for the treatment of schizoaffective disorder as monotherapy and an adjunct to mood stabilizers and/or antidepressant therapy [see clinical studies (14.2)] . the efficacy of paliperidone extended-release tablets in schizoaffective disorder was established in two 6-week trials in adults.  paliperidone is contraindicated in patients with a known hypersensitivity to either paliperidone or risperidone, or to any of the excipients in the paliperidone extended-release tablet formulation. hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported in patients treated with risperidone and in patients treated

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

tris pharma inc - paliperidone (unii: 838f01t721) (paliperidone - unii:838f01t721) - paliperidone extended-release tablets are indicated for the treatment of schizophrenia [see clinical studies (14.1)] . the efficacy of paliperidone extended-release tablets in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents, as well as one maintenance trial in adults. paliperidone extended-release tablets are indicated for the treatment of schizoaffective disorder as monotherapy and an adjunct to mood stabilizers and/or antidepressant therapy [see clinical studies (14.2)] . the efficacy of paliperidone extended-release tablets in schizoaffective disorder was established in two 6-week trials in adults. paliperidone extended-release tablets are contraindicated in patients with a known hypersensitivity to either paliperidone or risperidone, or to any of the excipients in the paliperidone extended-release tablets formulation. hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported in patients treated with risperidone and in

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

archis pharma llc - paliperidone (unii: 838f01t721) (paliperidone - unii:838f01t721) - paliperidone extended-release tablets are indicated for the treatment of schizophrenia [see clinical studies (14.1)] . the efficacy of paliperidone extended-release tablets in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents, as well as one maintenance trial in adults. paliperidone extended-release tablets are indicated for the treatment of schizoaffective disorder as monotherapy and an adjunct to mood stabilizers and/or antidepressant therapy [see clinical studies (14.2)] . the efficacy of paliperidone extended-release tablets in schizoaffective disorder was established in two 6-week trials in adults. paliperidone extended-release tablets are contraindicated in patients with a known hypersensitivity to either paliperidone or risperidone, or to any of the excipients in the paliperidone extended-release tablets formulation. hypersensitivity reactions, including anaph

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - paliperidone (unii: 838f01t721) (paliperidone - unii:838f01t721) - paliperidone extended-release tablets are indicated for the treatment of schizophrenia [see clinical studies (14.1)] . the efficacy of paliperidone extended-release tablets in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents, as well as one maintenance trial in adults. paliperidone extended-release tablets are indicated for the treatment of schizoaffective disorder as monotherapy and an adjunct to mood stabilizers and/or antidepressant therapy [see clinical studies (14.2)] . the efficacy of paliperidone extended-release tablets in schizoaffective disorder was established in two 6-week trials in adults.  paliperidone is contraindicated in patients with a known hypersensitivity to either paliperidone or risperidone, or to any of the excipients in the paliperidone extended-release tablet formulation. hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported in patients treated with risperidone and in patients treated

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

northstar rxllc - paliperidone (unii: 838f01t721) (paliperidone - unii:838f01t721) - paliperidone extended-release tablets are indicated for the treatment of schizophrenia [see clinical studies (14.1)] . the efficacy of paliperidone extended-release tablets in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents, as well as one maintenance trial in adults. paliperidone extended-release tablets are indicated for the treatment of schizoaffective disorder as monotherapy and an adjunct to mood stabilizers and/or antidepressant therapy [see clinical studies (14.2)] . the efficacy of paliperidone extended-release tablets in schizoaffective disorder was established in two 6-week trials in adults.  paliperidone is contraindicated in patients with a known hypersensitivity to either paliperidone or risperidone, or to any of the excipients in the paliperidone extended-release tablet formulation. hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported in patients treated with risperidone and in patients treated

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

janssen pharmaceuticals, inc - paliperidone palmitate (unii: r8p8usm8fr) (paliperidone - unii:838f01t721) - paliperidone palmitate 273 mg in 0.875 ml - invega trinza® (paliperidone palmitate), a 3-month injection, is indicated for the treatment of schizophrenia in patients after they have been adequately treated with invega sustenna® (1-month paliperidone palmitate extended-release injectable suspension) for at least four months [see dosage and administration (2.2) and clinical studies (14)] . invega trinza® is contraindicated in patients with a known hypersensitivity to either paliperidone or risperidone, or to any of the excipients in the invega trinza® formulation. hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported in patients treated with risperidone and in patients treated with paliperidone. paliperidone palmitate is converted to paliperidone, which is a metabolite of risperidone. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to atypical antipsychotics, including invega trinza® , during pregnancy. healthcare providers are encouraged to

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

janssen pharmaceuticals, inc. - paliperidone palmitate (unii: r8p8usm8fr) (paliperidone - unii:838f01t721) - paliperidone palmitate 39 mg in 0.25 ml - invega sustenna® (paliperidone palmitate) is indicated for the treatment of: - schizophrenia in adults [see clinical studies (14.1)]. - schizoaffective disorder in adults as monotherapy and as an adjunct to mood stabilizers or antidepressants [see clinical studies (14.2)]. invega sustenna® is contraindicated in patients with a known hypersensitivity to either paliperidone or risperidone, or to any of the excipients in the invega sustenna® formulation. hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported in patients treated with risperidone and in patients treated with paliperidone. paliperidone palmitate is converted to paliperidone, which is a metabolite of risperidone. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to atypical antipsychotics, including invega sustenna® , during pregnancy. healthcare providers are encouraged to register patients by contacting the national pregnancy registry for

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

ascent pharmaceuticals, inc. - paliperidone (unii: 838f01t721) (paliperidone - unii:838f01t721) - paliperidone extended-release tablets are indicated for the treatment of schizophrenia [see clinical studies (14.1)] . the efficacy of paliperidone in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents, as well as one maintenance trial in adults. paliperidone extended-release tablets are indicated for the treatment of schizoaffective disorder as monotherapy and an adjunct to mood stabilizers and/or antidepressant therapy [see clinical studies (14.2)] . the efficacy of paliperidone in schizoaffective disorder was established in two 6-week trials in adults. paliperidone extended-release tablets are contraindicated in patients with a known hypersensitivity to either paliperidone or risperidone, or to any of the excipients in the paliperidone extended-release tablets formulation. hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported in patients treated with risperidone and in patients treated with paliperidone. paliperidone

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

rebel distributors corp - paliperidone (unii: 838f01t721) (paliperidone - unii:838f01t721) - paliperidone 6 mg - invega® (paliperidone) extended-release tablets are indicated for the acute and maintenance treatment of schizophrenia [see clinical studies (14)] . monotherapy invega® (paliperidone) extended-release tablets are indicated for the acute treatment of schizoaffective disorder as monotherapy. adjunctive therapy invega® (paliperidone) extended-release tablets are indicated for the acute treatment of schizoaffective disorder as an adjunct to mood stabilizers and/or antidepressants. hypersensitivity reactions, including anaphylactic reactions and angioedema, have been observed in patients treated with risperidone and paliperidone. invega® (paliperidone) is a metabolite of risperidone and is therefore contraindicated in patients with a known hypersensitivity to either paliperidone or risperidone, or to any of the excipients in invega® . pregnancy category c . there are no adequate and well controlled studies of invega® in pregnant women. invega® should be used during pregnancy only if the potential benefit jus

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

janssen pharmaceuticals, inc. - paliperidone (unii: 838f01t721) (paliperidone - unii:838f01t721) - paliperidone 3 mg - invega ® (paliperidone) extended-release tablets are indicated for the treatment of schizophrenia [see clinical studies (14.1)] . the efficacy of invega ® in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents, as well as one maintenance trial in adults. invega ® (paliperidone) extended-release tablets are indicated for the treatment of schizoaffective disorder as monotherapy and an adjunct to mood stabilizers and/or antidepressant therapy [see clinical studies (14.2)] . the efficacy of invega ® in schizoaffective disorder was established in two 6-week trials in adults. invega ® is contraindicated in patients with a known hypersensitivity to either paliperidone or risperidone, or to any of the excipients in the invega ® formulation. hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported in patients treated with risperidone and in patients treated with paliperidone. pali